Evonik's Post-Bid Scorecard: A 19-Euro Target, a 24-Euro Memory and a 2027 Deadline in Indiana
Published on 11/22/2026 at 14:22 | Editorial boerse-global.deEvonik shareholders spent the back half of last week recalibrating what the specialty chemicals maker is worth on its own merits. The trigger was BASF's decision on Thursday to walk away from a takeover attempt, a retreat that sent the shares down 16% in a single session, according to Reuters. The stock gave up more ground on Friday and closed at €18.18.
The bid that never was had two iterations. BASF tabled two non-binding all-cash offers, both of which Evonik's board rejected; the final one stood at €24 per share, valuing the company at roughly €11.2 billion. Reuters reported that BASF saw no room to raise its price given the prospects and risks of a standalone Evonik. Interim chief executive Claus Rettig, speaking after the withdrawal, said the group would now concentrate fully on developing on its own — and, per Reuters, that the end of the process removes a source of uncertainty for employees.
Oddo Sets a New Benchmark Below the Old Bid
Analysts moved quickly to reset expectations. Oddo BHF cut Evonik to "Neutral" from "Outperform" on Friday and trimmed its price target to €19 from €22, citing the limited upside once the takeover effort had collapsed. The new marker sits below the €24 that BASF had last floated — a reminder that the offer priced what a suitor was prepared to pay, not what the business can generate by itself.
The largest shareholder is also adjusting its stance. RAG-Stiftung reaffirmed on Friday that it intends to reduce its stake step by step to 25.1%, while expressing regret that the two boards never held in-depth exploratory talks. IG BCE, for its part, urged the foundation to anchor that minimum holding permanently in its statutes and to contribute more to growth and investment at Evonik going forward.
Should investors sell immediately? Or is it worth buying Evonik?
Lafayette Becomes the Standalone Litmus Test
With no bid on the table, attention shifts to operations — and to a single site in Indiana. On 16 November, Evonik reported the first GMP-compliant production of PhytoChol at its new Lipid Innovation Center in Lafayette. For the equity, the first batch matters far less than whether the capacity build-out turns into a commercially meaningful contribution.
That distinction is the crux. Being able to produce and being able to sell profitably are two different things. The plant only gains significance beyond a technical milestone if output can be scaled and the additional volume meets adequate demand.
Management's case is straightforward: the BASF exit clears the decks, and Rettig has pledged to pursue standalone development at full force. Whether that direction justifies a richer valuation depends on what the company actually earns on its investments. In the best case, Lafayette ramps as planned and the extra production finds buyers at economically viable terms, giving the stock a basis for appraisal rooted in its own prospects rather than the terms of a withdrawn offer.
The Risk Is Not Only Delay
A slower ramp is the obvious hazard. The subtler one is a plant that hits its numbers while adding little to the bottom line — if demand fails to grow alongside supply, or if incremental volumes can only be placed at terms that barely move earnings. In that scenario the production target is met without producing a convincing case for a higher multiple. One site would not have to carry the entire re-rating; its initial value to investors lies in delivering verifiable progress, proof that a production start can be converted into reliable sales.
Oddo's downgrade illustrates how muted the view of upside can be absent a deal, though it is not a forecast for Lafayette — it sets the bar that operating progress must clear.
Evonik at a turning point? This analysis reveals what investors need to know now.
Mid-2027 Is the Next Fixed Date
Full production capacity at Lafayette is scheduled for mid-2027, giving investors their next concrete anchor. As long as the build-out stays on track, an additional earnings contribution remains plausible. More telling than hitting full capacity would be evidence that Evonik can use it profitably. Should the ramp slip or demand lag available capacity, this leg of the standalone growth story loses weight; should expansion and commercial utilisation arrive together, the company would have an operating argument for a re-rating.
That is the decision facing shareholders: whether production progress alone is enough, or whether only a visible earnings contribution makes the independent valuation convincing.
Ad
Evonik Stock: New Analysis - 22 November
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
